---
title: "TransMedics Group, Inc. (TMDX.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/TMDX.US/overview.md"
symbol: "TMDX.US"
name: "TransMedics Group, Inc."
parent: "https://longbridge.com/zh-HK/quote/TMDX.US.md"
datetime: "2026-04-05T02:44:48.737Z"
locales:
  - [en](https://longbridge.com/en/quote/TMDX.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TMDX.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TMDX.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/TMDX.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/TMDX.US/overview.md)


# TransMedics Group, Inc. (TMDX.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Health Care Equipment |
| 交易所 | US Market |
| 地址 | 200 Minuteman Road, Suite 302, Andover, Massachusetts, United States |
| 官網 | [www.transmedics.com](https://www.transmedics.com) |

## 公司簡介

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Waleed H. Hassanein | Founder, President, CEO & Director |
| James R. Tobin | Independent Chairman |
| Gerardo Hernandez | CFO & Treasurer |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
| Tamer I. Khayal | Chief Commercial Officer |
| Anil Ranganath | Advisor |
| Thomas J. Gunderson | Independent Director |
| Edward M. Basile | Independent Director |
| Merilee Raines | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| BlackRock, Inc. | 15.73% | 2025-12-31 |
| FMR LLC | 14.80% | 2025-12-31 |
| The Vanguard Group, Inc. | 10.51% | 2025-12-31 |
| UBS Asset Management AG | 4.83% | 2025-12-31 |
| State Street Global Advisors, Inc. | 3.72% | 2025-12-31 |
| Macquarie Investment Management Business Trust | 2.43% | 2025-12-31 |
| Geode Capital Management, LLC | 2.38% | 2025-12-31 |
| Driehaus Capital Management LLC | 2.08% | 2025-12-31 |
| Hood River Capital Management LLC | 2.01% | 2025-12-31 |
| Goldman Sachs Asset Management, L.P. | 1.92% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| Surgical & Medical Equipment | 605494000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "TransMedics Group, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Surgical & Medical Equipment",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| United States | 584697000 | 97.22% |
| ALL Other Countries | 16700000 | 2.78% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**